Companies / Kyntra Bio, Inc.

Kyntra Bio, Inc.

Nasdaq: KYNBCIK 921299SAN FRANCISCO, CA

Financials · FY2025

Revenue$6.44M
Net income$183.45M
Total debt$75.00M
Cash$50.64M
Diluted EPS$45.37
Shares outstanding4.0M

Ownership

4.0M shares outstanding · as of Apr 30, 2026
0.71%Insiders
Ownership
Insiders0.71%28,832
10%+ / strategic9.88%400,000
Institutions18.20%736,936
Public float71.20%2,882,344

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Wettig ThaneCEOCEO · Director
0.60%24,403
DeLucia DavidChief Financial Officer
0.11%4,429

Institutional holders 33

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 6, 2026Wettig Thane
CEO
OtherCommon Stock$1.9K-277
-1.12%
24,403
0.60% of shares
low
Mar 6, 2026DeLucia David
Executive
OtherCommon Stock$410-60
-1.34%
4,429
0.11% of shares
low
Jun 12, 2026Kauffman Michael
Director
GrantStock Option (Right to Buy)+7K
7,000
0.17% of shares
low
Jun 12, 2026Edwards Jeffrey L
Director
GrantStock Option (Right to Buy)+7K
7,000
0.17% of shares
low
Feb 3, 2026DeLucia David
Executive
GrantStock Option (Right to Buy)+26K
26,000
0.64% of shares
low
Feb 3, 2026Wettig Thane
CEO
GrantStock Option (Right to Buy)+60K
60,000
1.48% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Armistice Capital, LLCPassive13G/A400,000

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
KYNBCommon StockEquity31572Q881BBG000FW5ZL6